1173 / 1631
Therapy
Efficacy
Toxicity
Ocular RT (30-40 Gy) Rare local recurrence 60-
95% RR; no impact on OS
Cataracts, dry eyes,
retinopathy (mild)
HD-MTX
~50% sustained response,
poor vitreous penetration
Mild
HD-MTX+ RT both
eyes
100% CR
Cataracts, dry eyes,
retinopathy
Intensive chemo (EA)
+ASCT (TBC)
>50% response to EA;
6/10CR
Neurologic toxicity,
hemorrhage, VOD
Intravitreal rituximab or
MTX
Requires>6 injections to
achieve CR;
investigational
Conjunctival
keratopathy, cataracts,
optic atrophy,
endophthalmitis
Rubenstein et al. Blood 2013